Modulight OyjOMXHEX: MODU

Correction: 1Q26 Interim Report

· Issued by Modulight Oyj

Summary by 6ix AI

Modulight Corporation, which makes laser devices for treating cancer and eye diseases, corrected an error in how current liabilities were presented in the balance sheet of its financial statements released on April 24, 2026.

Key details

  • Accrued expenses are corrected to EUR 1,447 thousand from the published EUR 1,085 thousand.
  • Total current liabilities are corrected to EUR 3,451 thousand from the published EUR 1,949 thousand.
  • Total liabilities are unchanged at EUR 4,439 thousand. Modulight says the correction does not affect total assets, shareholders' equity, cash flow, operating result, profit for the financial year or any previously reported key performance indicators.
  • Other liability lines are unchanged, including current loans from financial institutions of EUR 1,502 thousand and non-current loans from financial institutions of EUR 988 thousand.

6ix AI wrote this summary from the release below and checked it against the release.

Modulight Corporation | Company Release | June 05, 2026 at 11:42:00 EEST

Modulight has identified an error in the presentation of certain balance sheet items in the financial statements released on 24-Apr-2026.

The error relates to the presentation of current liabilities. The amounts reported under accrued expenses and total current liabilities were incorrect.

The correct figures are as follows (EUR thousand):

Balance sheet itemPublished figureCorrect figureLiabilities    Non-current liabilities        Loans from financial institutions988988  Total non-current liabilities988988  Current liabilities        Loans from financial institutions1,5021,502      Advances received5353      Accounts payable285285     Other liabilities164164     Accrued expenses1,0851,447   Total current liabilities1,9493,451Total liabilities4,4394,439

The correction does not affect the Company's total liabilities, total assets, shareholders' equity, cash flow, operating result, profit for the financial year, or any previously reported key performance indicators. The correction concerns only the presentation of balance sheet items.

The corrected figures have been updated in the financial statements available on the Company's website.

The Company regrets the error.

For further information, please contact:

CEO Seppo Orsila, m. +358 40 830 4671

IR Ulla Haapanen, m. +358 40 830 4676

Email:

Certified adviser: Sisu Partners Oy, m. +358 40 555 4727

modulight.com

@modulight

Modulight in brief

Modulight Corporation is a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases. The company also manufactures products for other high value-add applications including flow cytometry, microscopy, semiconductor, quantum, and defense. The company’s products include medical devices, subsystems, software, cloud services, and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.

Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #KillCancer

Modulight Oyj on 6ix

Story so far

Earlier from Modulight

All Modulight news releases